- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01216345
Cetuximab + Gemox in Biliary Tract Cancer
October 6, 2010 updated by: Association of Research on the Biology of Liver Tumors
Cetuximab Plus Gemcitabine-Oxaliplatin (GEMOX) in Patients With Unresectable Advanced or Metastatic Biliary Tract Cancer: a Phase II Study
The aim of this prospective single-centre phase II study is to investigate the therapeutic efficacy and safety of cetuximab in combination with Gemcitabine and Oxaliplatin (GEMOX) in the palliative first line treatment of biliary tract cancer (BTC) patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Primary Objective(s) The primary objective of the study is to evaluate the best overall response of cetuximab in combination with gemcitabine and oxaliplatin (GEMOX) as first line treatment in patients with advanced or metastatic biliary tract cancer.
Secondary Objectives
The secondary objectives of this study are as follows:
- toxicity
- secondary resection rate
- progression-free survival (PFS)
- overall survival (OS)
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Vienna, Austria, 1030
- KH Rudolfstiftung
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- histologically or cytologically proven unresectable advanced or metastatic biliary tract cancer (including intrahepatic and extrahepatic CC and gallbladder cancer)
- age ≥ 18 years
- ECOG performance status ≤ 2
- bidimensionally measurable disease per RECIST criteria
- no prior chemotherapy or targeted therapy for advanced disease
- adequate bone marrow reserve (neutrophil count > 1500 /µL, platelet count > 100,000 /µL)
- adequate renal function (serum creatinine ≤ 1.5 x the upper limit of normal)
- adequate hepatic function (serum bilirubin <2.5 x the upper limit of normal (ULN) and serum transaminase level of ≤ 5 x ULN)
- written informed consent
Exclusion Criteria:
- prior palliative treatment
- resectable disease
- brain metastases
- serious or uncontrolled concurrent medical illness
- pregnancy or nursing
- history of other malignancies with the exception of excised cervical or basal skin/squamous cell carcinoma
- peripheral neuropathy (grade > 1)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
best overall response (according to RECIST 1.0)
Time Frame: after an average of 2 months
|
overall response rate (ORR) will be measured after each 4 cycles (average 2 months) of Cetuximab +GEMOX and the overall best response recorded
|
after an average of 2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of the treatment combination
Time Frame: approximately 6 months
|
approximately 6 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Gruenberger B, Schueller J, et al: K-ras status and response in patients with advanced or metastatic cholangiocarcinoma treated with cetuximab plus gemcitabine-oxaliplatin (GEMOX): a single center phase II study J Clin Oncol 27:15s, 2009 (suppl; abstr 4586)
- Gruenberger B, Schueller J, Heubrandtner U, Wrba F, Tamandl D, Kaczirek K, Roka R, Freimann-Pircher S, Gruenberger T. Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study. Lancet Oncol. 2010 Dec;11(12):1142-8. doi: 10.1016/S1470-2045(10)70247-3. Epub 2010 Nov 9.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Primary Completion (Actual)
October 1, 2008
Study Completion (Actual)
October 1, 2009
Study Registration Dates
First Submitted
October 4, 2010
First Submitted That Met QC Criteria
October 6, 2010
First Posted (Estimate)
October 7, 2010
Study Record Updates
Last Update Posted (Estimate)
October 7, 2010
Last Update Submitted That Met QC Criteria
October 6, 2010
Last Verified
October 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Digestive System Neoplasms
- Biliary Tract Diseases
- Biliary Tract Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Gemcitabine
- Oxaliplatin
- Cetuximab
Other Study ID Numbers
- CCC 01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic
-
Gustave Roussy, Cancer Campus, Grand ParisCompletedGIST Metastatic Cancer | Breast Metastatic Cancer | Kidney Metastatic Cancer | Colon Metastatic Cancer | Rectal Metastatic CancerFrance
-
Orion Biotechnology Polska Sp. z o.o.Not yet recruitingMetastatic Colorectal Cancer | Metastatic Cancer | Metastatic Breast Cancer | Metastatic Urothelial Carcinoma | Metastatic Gastric Cancer | Metastatic Pancreatic Cancer
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingSolid Tumor | Metastatic Cancer | Metastatic Solid Tumor | Solid Tumor, Adult | Solid Carcinoma | Metastatic TumorUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingAdvanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Metastatic Malignant Neoplasm in the Liver | Metastatic Malignant Neoplasm in the LungUnited States
-
Advaxis, Inc.TerminatedMetastatic Melanoma | Urothelial Carcinoma | Metastatic Non-Small Cell Lung Cancer | Head and Neck Cancer Metastatic | Colon Cancer MetastaticUnited States
-
Memorial Sloan Kettering Cancer CenterRecruitingMetastatic Solid Tumors of Metastatic DiseaseUnited States
-
Gottfried MayaUnknownMetastatic Lung Cancer | Metastatic Breast Cancer | Metastatic Prostate Cancer | Metastatic Gastric Cancer | Metastatic Bladder CancerIsrael
-
Albert Einstein College of MedicineTerminatedCancer | Solid Tumor | Metastatic Solid Tumor | Metastatic dMMR Solid CancerUnited States
-
Institut de Cancérologie de la LoireSaint-Louis Hospital, Paris, France; Gustave Roussy, Cancer Campus, Grand ParisWithdrawnMetastatic Colorectal Cancer | Metastatic Breast Cancer | Metastatic Head and Neck CancerFrance
-
Valley Health SystemRecruitingMetastatic Solid Tumor | Cancer MetastaticUnited States
Clinical Trials on Cetuximab + Gemcitabine + Oxaliplatin
-
Dorte NielsenCompletedCholangiocarcinomaDenmark
-
National Health Research Institutes, TaiwanNational Taiwan University Hospital; Mackay Memorial Hospital; China Medical... and other collaboratorsCompletedCholangiocarcinoma | Adenocarcinoma of GallbladderTaiwan
-
Central European Cooperative Oncology GroupCompletedColorectal CancerIsrael, Austria, Croatia, Greece, Serbia, Bosnia and Herzegovina, Bulgaria, Estonia, Hungary, Latvia, Romania, Slovakia, Slovenia
-
US Oncology ResearchEli Lilly and Company; SanofiCompleted
-
3D Medicines (Sichuan) Co., Ltd.RecruitingBiliary Tract NeoplasmsChina
-
National University Hospital, SingaporeUnknown
-
Medical University of South CarolinaCompleted
-
Swiss Group for Clinical Cancer ResearchCompleted
-
Abramson Cancer Center of the University of PennsylvaniaBristol-Myers Squibb; Roche Pharma AGTerminated
-
University of MiamiCompletedPancreatic CancerUnited States